Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Sept. 5, 2014, 83 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,476.00 to $43,857,000.00.

Highlighted Stocks Traded by Insiders:

MWI Veterinary Supply (MWIV) - FREE Research Report

Sutherland Alden J, who is VP and CIO at MWI Veterinary Supply, sold 277 shares at $143.98 on Sept. 5, 2014. Following this transaction, the VP and CIO owned 4,544 shares meaning that the stake was reduced by 5.75% with the 277-share transaction.

The shares most recently traded at $144.81, up $0.83, or 0.58% since the insider transaction. Historical insider transactions for MWI Veterinary Supply go as follows:

  • 4-Week # shares bought: 300
  • 4-Week # shares sold: 275
  • 12-Week # shares bought: 300
  • 12-Week # shares sold: 275
  • 24-Week # shares bought: 300
  • 24-Week # shares sold: 275

The average volume for MWI Veterinary Supply has been 74,800 shares per day over the past 30 days. MWI Veterinary Supply has a market cap of $1.8 billion and is part of the services sector and wholesale industry. Shares are down 15.86% year-to-date as of the close of trading on Friday.

MWI Veterinary Supply, Inc., together with its subsidiaries, distributes animal health products to veterinarians in the United States and the United Kingdom. The company has a P/E ratio of 26.6. Currently, there are 5 analysts who rate MWI Veterinary Supply a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MWIV - FREE

TheStreet Quant Ratings rates MWI Veterinary Supply as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full MWI Veterinary Supply Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BioDelivery Sciences International (BDSI) - FREE Research Report

Sirgo Mark A, who is President and CEO at BioDelivery Sciences International, bought 2,000 shares at $15.04 on Sept. 5, 2014. Following this transaction, the President and CEO owned 922,102 shares meaning that the stake was boosted by 0.22% with the 2,000-share transaction.

The shares most recently traded at $17.50, up $2.46, or 14.06% since the insider transaction. Historical insider transactions for BioDelivery Sciences International go as follows:

  • 4-Week # shares bought: 1,800
  • 4-Week # shares sold: 89,386
  • 12-Week # shares bought: 3,050
  • 12-Week # shares sold: 89,386
  • 24-Week # shares bought: 3,050
  • 24-Week # shares sold: 94,386

The average volume for BioDelivery Sciences International has been 1.2 million shares per day over the past 30 days. BioDelivery Sciences International has a market cap of $739.0 million and is part of the health care sector and drugs industry. Shares are up 177.25% year-to-date as of the close of trading on Friday.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care. Currently, there are 5 analysts who rate BioDelivery Sciences International a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BDSI - FREE

TheStreet Quant Ratings rates BioDelivery Sciences International as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full BioDelivery Sciences International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Virtus Investment Partners (VRTS) - FREE Research Report

Angerthal Michael A, who is EVP, Chief Financial Officer at Virtus Investment Partners, bought 135 shares at $179.77 on Sept. 5, 2014. Following this transaction, the EVP, Chief Financial Officer owned 34,614 shares meaning that the stake was boosted by 0.39% with the 135-share transaction.

The shares most recently traded at $186.81, up $7.04, or 3.77% since the insider transaction. Historical insider transactions for Virtus Investment Partners go as follows:

  • 4-Week # shares sold: 3,550
  • 12-Week # shares sold: 3,550
  • 24-Week # shares sold: 3,550

The average volume for Virtus Investment Partners has been 45,000 shares per day over the past 30 days. Virtus Investment Partners has a market cap of $1.9 billion and is part of the financial sector and financial services industry. Shares are down 7.52% year-to-date as of the close of trading on Friday.

Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The stock currently has a dividend yield of 0.88%. The company has a P/E ratio of 21.1. Currently, there is 1 analyst who rates Virtus Investment Partners a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTS - FREE

TheStreet Quant Ratings rates Virtus Investment Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, growth in earnings per share, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Virtus Investment Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null